Siri AI rolls out, but Europe launch is delayed as GSK moves to buy Nuvalent for $10.6 billion in cash

Markets were mixed in late-morning trading as chip-stock momentum cooled, with the Dow Jones Industrial Average rising while the S&P 500 and Nasdaq Composite declined, according to a market roundup carried by Yahoo Finance.

In corporate news, GlaxoSmithKline said it would acquire Nuvalent for $10.6 billion in cash, a move that underscores how large drugmakers are looking to add late-stage oncology assets and new precision medicines through acquisitions rather than relying only on internal pipelines.

Apple, meanwhile, drew attention for consumer and technology developments. The company introduced an upgraded Siri that uses artificial intelligence, positioning it as a more capable assistant that can respond to requests with greater context and more natural interactions than traditional voice commands.

Apple’s announcement also included a regional timing difference. The EU launch of the new Siri AI is expected to be delayed compared with other markets, reflecting the reality that new consumer AI features often face additional review and compliance steps in Europe, where regulators have been scrutinizing how AI systems are deployed.

Neither Apple nor GlaxoSmithKline’s details were fully spelled out in the market roundup itself. For example, the Yahoo Finance post summarized the direction of the EU rollout but did not provide a specific launch date or describe which parts of Siri’s capabilities would arrive first.

For GSK, the roundup highlighted the headline price and the cash nature of the offer, but it did not outline deal terms such as expected regulatory timelines, financing structure, or whether the company expects any specific integration plan or cost synergies to be realized in the near term.

Taken together, the day’s developments reflect two parallel pressures shaping business strategy. In technology, companies are racing to bring AI assistants into the mainstream, but regional constraints can slow availability. In healthcare, scale and speed are driving consolidation, with large buyers paying big premiums for targeted therapeutic platforms.